Fresh, sourced stories worth posting about for medical device professionals — updated every few hours, with the receipts attached. Not generated guesses.
Your desk is ready
Free to start · no card required · your pick is waiting on the other side.
Niche's weekly rollup — one email, no spam.
The stories refresh every few hours from live news and primary sources. Each carries the publisher and the date it was published — so you can see exactly how current it is.
Real reporting and primary filings — every story links its sources. Nothing here is a generated guess; the angle is identified and the receipts are attached.
Yes. These are starting points for your own posts. Draft one and Niche writes it in your voice, platform-native, ready to publish.
Boston Scientific shows up in multiple clinical programs spanning TheraSphere in hepatocellular carcinoma, a post-approval dosimetry study, and the RHAPSODY rhythm mapping study, highlighting the company's active clinical evidence generation across oncology and electrophysiology.
Draft a post from this →Multiple NCI-sponsored trials are active or recruiting across melanoma, Merkel cell carcinoma, head and neck cancer, gastric and esophageal cancer, Hodgkin lymphoma, and breast cancer, reflecting a broad late-stage oncology development cycle with several combination-immunotherapy strategies.
Draft a post from this →A mix of device-adjacent and therapeutic studies shows continued activity in cardiac rhythm and cardiovascular care, led by Boston Scientific's RHAPSODY study and broader cardiovascular health research funding, with macro conditions also reminding investors that rates remain elevated.
Draft a post from this →A mix of self-collection HPV testing and other prevention-oriented research signals continued interest in simpler testing workflows, while medtech-adjacent research activity suggests ongoing innovation in diagnostics and care pathways.
Draft a post from this →